SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Pulmonology Consultation — Satchel Paige

PatientSatchel Paige
Date of birth1953-07-07
IdentifiersMRN HR-ML047-SYN; SSN (made up) 000-47-3381
Document date2026-07-28
AuthorMarcus Lindqvist-Bello, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Referral

Two years of breathlessness on exertion (mMRC 2) and a morning cough in a 73-year-old former smoker of about 30 pack-years, with a normal NT-proBNP and ECG. Please confirm or exclude COPD with spirometry interpreted with race-neutral equations, and advise on treatment, oxygen, rehabilitation and screening. [S]

Urgency: Routine, within two to three weeks. [S]

Questions for the consultant:

History of Present Illness

Mr. Paige, 73, a retired professional pitcher and former smoker of about 30 pack-years who stopped eleven years ago, is seen at the request of Dr. Whitaker-Osei for two years of breathlessness on exertion and a morning cough. He has had no exacerbations in the past year. Albuterol, started two weeks ago, helps before walks; he uses it once or twice a day. No chest pain, orthopnea or ankle swelling. He asked to see his results and how they are calculated. [S]

Historical basis. These claims are historical evidence, not findings from a modern examination.

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 micrograms per inhalation metered-dose inhaler with a spacer, two inhalations every four hours as needed for breathlessnessTwo inhalations with a spacer every 4 hours as neededRespiratory tract route2026-07-14activeS
Umeclidinium 62.5 micrograms with vilanterol 25 micrograms dry powder inhaler (a LAMA with a LABA), one inhalation once a dayOne inhalation each morning; a strong, deep breath inRespiratory tract route2026-07-28activeS
Atorvastatin 20 mg tablet once a dayOne tablet each eveningOral route2026-07-14activeS

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness on exertion for about two years, now after one flight of stairs or a block on the level (mMRC 2), with a morning cough and a little clear sputum most days; no chest pain, ankle swelling, orthopnea, wheeze at rest or weight loss; a former smoker of about 30 pack-years; cause under evaluation with spirometry and a pulmonology consultationresolvedconfirmed R06.09S — Synthetic presenting problem anchored to his documented emphysema; superseded when spirometry at the consultation confirmed COPD.
Chronic obstructive pulmonary disease, GOLD grade 2 (post-bronchodilator FEV1/FVC 0.58, FEV1 61% predicted by the race-neutral GLI Global equations), GOLD group B (CAT 18, mMRC 2, no exacerbation in the past year); alpha-1 antitrypsin normal; blood eosinophils 0.08 x 10^3/uL; synthetic modern diagnosis linked to his documented emphysemaactiveconfirmed J44.9S — Synthetic modern diagnosis made at the consultation, anchored to his documented emphysema; its onset and course in the modern episode are synthetic.
Former cigarette smoker, about 30 pack-years, stopped eleven years ago on his own; no use sinceactiveconfirmed Z87.891S — Synthetic smoking history: whether he smoked is not documented in the sources read, so the history is synthetic and labeled as such.
Hyperlipidemia: LDL 148 mg/dL, HDL 44 and triglycerides 160 at intake; estimated 10-year cardiovascular risk about 18 percent; atorvastatin started by shared decisionactiveconfirmed E78.5S — Synthetic cardiovascular risk factor anchored to his documented heart trouble; not a claim about his real lipids.

Physical Exam

Vital signs recorded on 2026-07-28; see the referring visit's Vital Signs section. [S]

SystemFinding
GeneralTall, lean and alert; full sentences; oxygen saturation 94 percent on room air
ChestBarrel-shaped; reduced breath sounds throughout with prolonged expiration; no wheeze or crackles
CardiovascularRegular rhythm; soft heart sounds; no raised jugular venous pressure or edema
HandsNo clubbing

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-28FEV1 --pre bronchodilation1.92LLower limit of normal, GLI Global (race-neutral) for age, sex and heightLowS
2026-07-28FEV1 --post bronchodilation2.02LLower limit of normal, GLI Global (race-neutral)LowS
2026-07-28Forced vital capacity [Volume] Respiratory system --post bronchodilation3.48LLower limit of normal, GLI Global (race-neutral)NormalS
2026-07-28FEV1/FVC --post bronchodilation0.58{ratio}GOLD fixed ratio 0.70; post-bronchodilator ratio below 0.70 confirms airflow obstruction (GLI Global lower limit of normal about 0.62)LowS
2026-07-28FEV1 measured/predicted61%GOLD grade 1 at 80% or more, grade 2 at 50 to 79%LowS
2026-07-28pH of Arterial blood7.42[pH]7.35-7.45 [pH]NormalS
2026-07-28Carbon dioxide [Partial pressure] in Arterial blood40mm[Hg]35-45 mmHgNormalS
2026-07-28Oxygen [Partial pressure] in Arterial blood70mm[Hg]Long-term oxygen threshold: 55 mm Hg or less (60 or less with cor pulmonale or polycythemia)LowS
2026-07-28Six minute walk test360mPredicted about 520 m for his age, sex and height; lower limit about 400 mLowS

Assessment

Data reviewed: Dr. Whitaker-Osei's intake note and results: eosinophils 0.08 x 10^3/uL, alpha-1 antitrypsin 142 mg/dL, NT-proBNP 92 pg/mL, a normal ECG, hemoglobin 15.2 g/dL. Today: spirometry meeting ATS/ERS quality standards, FEV1 1.92 L before and 2.02 L after 400 micrograms of albuterol, FVC 3.48 L, post-bronchodilator FEV1/FVC 0.58, FEV1 61% of the GLI Global predicted value; room-air arterial blood gas pH 7.42, PaCO2 40 mm Hg, PaO2 70 mm Hg; six-minute walk 360 m with a lowest saturation of 90 percent; CAT 18, mMRC 2. [S]

Plan of Treatment